Taken together, our data and previously published data strongly demonstrate that CXCR2 ligands are produced in high quantity from PDAC tumors and promote the recruitment and/or retention and differentiation of CXCR2+ MDSCs, which counteract anti-tumor immunity. The gene discussed is CXCR2; the disease is neoplasm.